AU2004323577A1 - Carrier-free composition for the treatment of onychomycosis - Google Patents

Carrier-free composition for the treatment of onychomycosis Download PDF

Info

Publication number
AU2004323577A1
AU2004323577A1 AU2004323577A AU2004323577A AU2004323577A1 AU 2004323577 A1 AU2004323577 A1 AU 2004323577A1 AU 2004323577 A AU2004323577 A AU 2004323577A AU 2004323577 A AU2004323577 A AU 2004323577A AU 2004323577 A1 AU2004323577 A1 AU 2004323577A1
Authority
AU
Australia
Prior art keywords
composition
ingredients
mixture
carrier
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2004323577A
Other versions
AU2004323577B2 (en
Inventor
Nair G. Muraleedharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University MSU
Original Assignee
Michigan State University MSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University MSU filed Critical Michigan State University MSU
Publication of AU2004323577A1 publication Critical patent/AU2004323577A1/en
Application granted granted Critical
Publication of AU2004323577B2 publication Critical patent/AU2004323577B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125Camphor; Nuclear substituted derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Description

WO 2006/036144 PCT/US2004/031630 CARRIER-FREE COMPOSITION FOR THE TREATMENT OF ONYCHOMYCOSIS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] Not Applicable STATEMENT REGARDING GOVERNMENT RIGHTS [0003] Not Applicable BACKGROUND OF THE INVENTION (1) Field of the Invention [0004] The present invention relates to a carrier-free composition which is an onychomycosis (fungal nail disease) therapeutic agent. In particular, the present invention relates to a composition consisting essentially of thymol, camphor, menthol and Eucalyptus citridiora oil. (2) Description of the Related Art [0005] U.S. Patent No. 6,344,190 to Nair et al describes the use of camphor, menthol, eucalyptus and thymol with a carrier which is a solvent for the ingredients; particularly, an ester of an alcohol such as isoamyl alcohol. This was done to solubilize the ingredients. It was thought that the carrier was necessary for this purpose. OBJECTS [0006] It is therefore an object of the present invention to provide a carrier-free composition wherein the ingredients are solubilized to provide a clear solution. It -1- WO2006/036144 PCT/US2004/031630 is further an object of the present invention to provide a method for the preparation of the composition. It is also an object of the present invention to provide a method for the use of the composition. These and other objects will become increasingly apparent by reference to the following description. SUMMARY OF THE INVENTION [0007] The present invention relates to a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier. Preferably, the composition contains equal parts by weight of the ingredients. Further, the composition of the colorless liquid has been provided by a method which comprises stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid. Still further, the composition of the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid. Preferably, the composition of the mixture has been heated up to about 80oC. [0008] Further, the present invention relates to a method for the preparation of a pharmaceutical composition which comprises: mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and treating the mixture to provide a colorless oil. Preferably, the present invention relates to the method wherein the treating is by heating the mixture. Still further, the present invention relates to the method wherein the treating is by mixing the ingredients over a period of time to provide the colorless mixture. [0009] Further still, the present invention relates to a method of treating toenail fungal infections which -2- WO2006/036144 PCT/US2004/031630 comprises: applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier. Preferably, the method of the composition contains equal parts of the ingredients. [0010] The substance and advantages of the present invention will become increasingly apparent by reference to the following description. DESCRIPTION OF THE PREFERRED EMBODIMENTS [0011] Equal weights of thymol, camphor, menthol and Eucalyptus citridiora oil were used to formulate the TNF therapeutic agent resulting to a clear liquid that penetrates the cuticles and nails. The Eucalyptus citridiora oil was weighed first and stirred with equal weights of solid thymol, menthol and camphor. The mixture was then warmed to 80oC till it forms a colorless liquid or stir at room temperature till the solids dissolve to form a colorless.liquid. The resulting product is easy to apply on infected nails using a nail polish applicator or by a cotton swab. [0012] Tests were performed with the composition on toenail fungi as follows: [0013] Components in the formulation were equal weights of the following compounds 1-4: -3- WO 2006/036144 PCT/US2004/031630
H
3 C CH 3
H
3 G O 1. Camphor
CH
3 OH
H
3 C CH3 2. Menthol OH
CH
3
CH
3
H
3 C 3. Thymol 4. E. citridiora oil -4- WO2006/036144 PCT/US2004/031630 [0014] Microbial cultures. All organisms, except the Fusarium and Candida spp., were purchased from American Type Culture Collection (ATCC), Manassas, Virginia, USA. The Fusarium and Candida spp. were Michigan State University (MSU) strains (Nair, M.G., Putnam, A.R., Mishra, S.K., Mulks, M.H., Taft, W.H., Keller, J.E., Miller, J.R., Zhu, P.P., Meinhart, J.D., Lynn, D.G. 1989. Faeriefungin: A new broad-spectrum antibiotic from Streptomyces griseus var. autotrophicus. J Nat Prod 52: 797-809). [0015] Antimicrobial assay. M. canis (ATCC 42888), E. floccosum (ATCC 44685) , F. oxysporum (MSU strain), F. proliferatum (MSU strain), A. chrysogenum (ATCC 22571), A. strictum (ATCC 46646), A. terreus (ATCC 52293), and A. flavus (ATCC 60040) were cultured in Petri dishes containing PDA medium (20 mL). T. rubrum (ATCC 28202), T. mentagrophytes (ATCC 42194), S. brevicaulis (ATCC 36139), and S. dimidiatum (ATCC 46921) were cultured in Petri dishes containing Emmon's modification of Sabouraud's agar medium (20 mL). S. hyalinum (ATCC 66093) was cultured in Petri dishes containing Malt extract agar medium (20 mL). The test organisms C. albicans (MSU strain), C. kruseii (MSU strain), and C. parapsilosis (MSU strain) were cultured in Petri dishes containing YMG media (20 mL). [0016] The cells from a fully- grown plate of each organism were suspended in saline solution (5 mL) and diluted to obtain 5 x 106 CFU/mL using a hemacytometer. 50 OL of this suspension was used to inoculate I mL of respective growth medium of each test organism. Test formulation was added to the inoculated tubes at concentrations ranging from 250 to 5 O1/mL. The tubes containing cell cultures and compounds were incubated at 27 'C for 72- 96 h. At the end of the incubation period, the tubes were examined for growth of the -5- WO2006/036144 PCT/US2004/031630 organism and further monitored for 7 days after which they were recorded for growth or no growth. The concentration at which no growth was observed or minimum concentration for 100 % inhibition (MIC 100oo) is shown in Table 1 for each organism. -6- WO 2006/036144 PCT/US2004/031630 Table 1. MICo 100 ( tg/mL) for the mixture containing equal weights of camphor, menthol, thymol and Eucalyptus citriodora oil against organisms causing onychomycosis. Organism MIC Acremonium chrysogenumn 20 A. strictum >20 >30 Aspergillus flavus A. terreus 30 Candida albicans' -50 C. kruseii >50 C. parapsilosis 50 >30 Epidermophyton floccosum Fusarium oxysporum 30 >30 F. proliferatum30 Microsporum canis >40 ?30 Scopulariopsis brevicaulis 30 >30 Scytalidiumn dimnzidiatum 30 S. hyalinum -30 >30 Trichophyton mentagrophytes 30 T. rubrunm >30 [0017] The composition had a very broad spectrum of activity as can be seen from the results. [0018] It is intended that the foregoing description be only illustrative of the present invention and that the present invention be limited only by the hereinafter appended claims. -7-

Claims (10)

1. A composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
2. The composition of Claim 1 wherein the composition contains equal parts by weight of the ingredients.
3. The composition of Claims 1 or 2 wherein the colorless liquid has been provided by stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid.
4. The composition of Claims 1 or 2 wherein the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid.
5. The composition of Claims 1 or 2 wherein the mixture has been heated up to about 80 0 C.
6. A method for the preparation of a pharmaceutical composition which comprises: (a) mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and 5 (b) treating the mixture to provide a colorless oil. -8- WO 2006/036144 PCT/US2004/031630
7. The method of Claim 6 wherein the treating is by heating the mixture.
8. The method of Claim 6 wherein the treating is by mixing the ingredients over a period of time to provide the colorless mixture.
9. A method of treating toenail fungal infections which comprises: applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
10. The method of Claim 9 wherein the composition contains equal parts of the ingredients. -9-
AU2004323577A 2004-09-24 Carrier-free composition for the treatment of onychomycosis Expired - Fee Related AU2004323577B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/031630 WO2006036144A1 (en) 2004-09-24 2004-09-24 Carrier-free composition for the treatment of onychomycosis

Publications (2)

Publication Number Publication Date
AU2004323577A1 true AU2004323577A1 (en) 2006-04-06
AU2004323577B2 AU2004323577B2 (en) 2009-02-12

Family

ID=

Also Published As

Publication number Publication date
CA2581606A1 (en) 2006-04-06
WO2006036144A1 (en) 2006-04-06
EP1796703A1 (en) 2007-06-20
JP2008514596A (en) 2008-05-08
EP1796703A4 (en) 2009-07-01
WO2006036144A8 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
US10980846B2 (en) Use of gram negative species to treat atopic dermatitis
Ramsewak et al. In vitro antagonistic activity of monoterpenes and their mixtures against ‘toe nail fungus’ pathogens
Faergemann et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis
RU2408372C2 (en) Application of octenidine dihydrochloride in semisolid preparations
US10653727B2 (en) Use of gram negative species to treat atopic dermatitis
US20210169943A1 (en) Use of gram negative species to treat atopic dermatitis
CN109789179A (en) The composition of topical application with antifungal activity
US7341747B2 (en) Carrier-free composition for the treatment of onychomycosis
Gayatri et al. Novel thiazolinyl-picolinamide-based palladium (II) complex extenuates the virulence and biofilms of vulvovaginal candidiasis (VVC) causing Candida
EP2429289A2 (en) Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products
CA2581606A1 (en) Carrier-free composition for the treatment of onychomycosis
Ansari et al. Design and evaluation of topical herbal antifungal stick containing extracts of Rhinacanthus nasutus
AU2004323577B2 (en) Carrier-free composition for the treatment of onychomycosis
Kanimozhi et al. Screening and evaluation of potential antifungal plant extracts against skin infecting fungus Trichophyton rubrum
JPS5832818A (en) Remedy for nail mycotic infection
Bairagi et al. Identification of Bacterial Population from Diabetic Wound of Mice to Study the Bactericidal Efficacy of Green Synthesized Silver Nanoparticle by Saraca asoca Bark Extract
Vargas Antibiofilm activity of essential oils in Candida spp.: a literature review
FR3111807A1 (en) Use of compounds derived from pyrido-pyrimidin-triones as agents preventing or reducing the adhesion of microorganisms to the skin and / or mucous membranes
CZ307642B6 (en) A preparation containing the viable mycoparasitic microorganism Pythium oligandrum for the treatment of dermatophytoses and yeast infections on the skin and mucous membranes and a method of application of the preparation

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee